Ocuphire Pharma Inc. (OCUP) Financial Statements (2025 and earlier)

Company Profile

Business Address 37000 GRAND RIVER AVE.
FARMINGTON HILLS, MI 48335
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments41,41447,16650,51642,36139,99939,010
Cash and cash equivalents41,40947,16150,50142,35039,97738,988
Short-term investments5515112222
Receivables1,3581,92492610,1321352,834
Prepaid expense1,0271,4719974336871,010
Other current assets8789102514578
Other undisclosed current assets9481,1941,4071,2112,5952,467
Total current assets:44,83451,84453,94854,18843,46145,399
Noncurrent Assets
Property, plant and equipment    345
Total noncurrent assets:    345
TOTAL ASSETS:44,83451,84453,94854,19143,46545,404
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities4,1245,7133,9683,8165,7614,154
Accounts payable6342,0642,1531,8902,3232,221
Accrued liabilities3,4903,6491,8151,9263,4381,933
Derivative instruments and hedges, liabilities74747493  
Total current liabilities:4,1985,7874,0423,9095,7614,154
Noncurrent Liabilities
Total liabilities:4,1985,7874,0423,9095,7614,154
Equity
Equity, attributable to parent40,63646,05749,90650,28237,70441,250
Common stock332222
Additional paid in capital136,970134,626131,370126,951119,934118,519
Accumulated deficit(96,337)(88,572)(81,466)(76,671)(82,232)(77,271)
Total equity:40,63646,05749,90650,28237,70441,250
TOTAL LIABILITIES AND EQUITY:44,83451,84453,94854,19143,46545,404

Income Statement (P&L) ($ in thousands)

9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
Revenues1,1121,7111,69111,9353,6741,749
Gross profit:1,1121,7111,69111,9353,6741,749
Operating expenses(9,440)(9,419)(7,120)(5,549)(9,063)(7,880)
Operating income (loss):(8,328)(7,708)(5,429)6,386(5,389)(6,131)
Nonoperating income563602632517428340
Other nonoperating income563602613456428340
Income (loss) from continuing operations before equity method investments, income taxes:(7,765)(7,106)(4,797)6,903(4,961)(5,791)
Other undisclosed loss from continuing operations before income taxes    (1,328)  
Income (loss) from continuing operations before income taxes:(7,765)(7,106)(4,797)5,575(4,961)(5,791)
Income tax expense (benefit)   2(14)  
Net income (loss) available to common stockholders, diluted:(7,765)(7,106)(4,795)5,561(4,961)(5,791)

Comprehensive Income ($ in thousands)

9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
Net income (loss):(7,765)(7,106)(4,795)5,561(4,961)(5,791)
Comprehensive income (loss), net of tax, attributable to parent:(7,765)(7,106)(4,795)5,561(4,961)(5,791)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: